Agora Open Science Trust announced nomination of M4K2009 as lead development candidate for pediatric brain cancer therapy

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Agora Open Science Trust recently announced the nomination of M4K2009 as the lead development candidate for its M4K Pharma program, which applies open science to drive the development of an affordable treatment for Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer. The selection of M4K2009 represents a significant scientific and organizational milestone.

Agora Open Science Trust is supported in part by Conscience. Conscience is among our industry partners supporting the 2026 OBIO® Investment Summit.

Read more
Arsheen Kaur
Previous

Two OBIO® companies join NATO's defence tech accelerator program
Next

Ontario welcomes $138 Million investment in the life sciences sector